Peptides are most stable in their glass vial
because rigorously controlled human safety data specific to the TB-500 fragment does not exist, its longer-term risk profile, including possible immune reactions, remains unknown Evidence snapshot: Evidence for TB-500 itself is preclinical, drawn mainly from cell-culture and animal studies (a 1999 rat wound-healing study and later rodent cardiac- and tendon-injury models), with a 2026 scoping review describing the musculoskeletal literature on thymosin beta-4 and TB-500 as sparse and largely preclinical

Research-grade specs Components: BPC-157 + TB-500 (equal amounts) 5 MG vial: BPC-157 5 mg + TB-500 5 mg (10 mg total) 10 MG vial: BPC-157 10 mg + TB-500 10 mg (20 mg total) Format: Lyophilized powder, single-vial blend Pathways studied: Cell migration and signalling (BPC-157), actin-binding (TB-500) Studied applications Comparative single-compound vs combined-mechanism research Cell migration and cytoskeletal pathway studies Peptide stability and reconstitution research Research replication of frequently cited two-peptide combinations Quality & trust 99% HPLC purity, third-party tested Mass spectrometry identity confirmation LAL endotoxin testing on every batch Batch-specific Certificate of Analysis included cGMP manufactured in Dallas, Texas (USA) USA same-day shipping (orders before 2pm CT M-F) Free domestic shipping on orders over $200 Storage & handling Store lyophilized vials refrigerated at 28C, protected from light and heat Reconstitute with bacteriostatic water

B12 is available in oral supplements, but it is recommended to get the shots because they are more effective than pills
With the BPC 157 application (Sikiric et al., 1993